Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.
The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), which include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis, originate from a stem cell-derived clonal myeloproliferation that manifests itself with variable haematopoietic cell lineage involvement; they are characterized by a high degree of similarities and the chance to transform each to the other and to evolve into acute leukaemia. Their molecular pathogenesis has been associated with recurrent acquired mutations in janus kinase 2 (JAK2) and myeloproliferative leukemia virus oncogene (MPL). These discoveries have simplified the diagnostic approach and provided a number of clues to understanding the phenotypic expression of MPNs; furthermore, they represented a framework for developing and/or testing in clinical trials small molecules acting as tyrosine kinase inhibitors. On the other hand, evidence of abnormal epigenetic gene regulation as a mechanism potentially contributing to the pathogenesis and the phenotypic diversity of MPNs is still scanty; however, study of epigenetics in MPNs represents an active field of research. The first clinical trials with epigenetic drugs have been completed recently, whereas others are still ongoing; results have been variable and at present do not allow any firm conclusion. Novel basic and translational information concerning epigenetic gene regulation in MPNs and the perspectives for therapy will be critically addressed in this review.
Vannucchi
Alessandro M
AM
UF di Ematologia, Dip. Area Critica Medico-Chirugica, Università di Firenze, Firenze, Italy. amvannucchi@unifi.it
Guglielmelli
Paola
P
Rambaldi
Alessandro
A
Bogani
Costanza
C
Barbui
Tiziano
T
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D044127:Epigenesis, Genetic; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics*; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology
D000970:Antineoplastic Agents